The funding supports eXoZymes’ Phase IIB SBIR program to develop modified cannabinoids for pharmaceutical applications starting mid-2026.
eXoZymes secured a $2.02M grant from the National Institutes of Health to advance cannabinoid analog research. The funding, part of a Phase IIB Small Business Innovation Research award, targets drug discovery efforts.
The NIH grant follows prior support for the company’s work on engineered cannabinoids, which are chemically altered for potential therapeutic use. The program is set to begin July 1, 2026, with no immediate market reaction reported.
The award underscores growing institutional interest in cannabinoid-based pharmaceutical development, though the company remains privately held.